Philips CPAP Machine

Philips CPAP machine models, including the widely used DreamStation and DreamStation 2, are continuous positive airway pressure devices designed to treat obstructive sleep apnea by delivering steady airflow to keep the airway open during sleep. The 2021 Philips Respironics recall affected millions of patients in the United States and globally, raising serious questions about the safety of PE-PUR sound abatement foam used inside these devices. According to the U.S. Food and Drug Administration, the recall covered more than 15 million devices across CPAP, BiPAP, and mechanical ventilator categories. This article is for sleep apnea patients, healthcare professionals, and anyone evaluating whether to continue, replace, or upgrade their respiratory care devices. It covers the full recall timeline, affected models, health risks, replacement options, regulatory actions, and how sleep disruption from untreated apnea accelerates biological aging, a connection that most recall coverage ignores entirely.

Quick Answer

Philips CPAP machines are positive airway pressure devices that treat obstructive sleep apnea by keeping the airway open during sleep. Philips Respironics recalled millions of CPAP, BiPAP, and ventilator devices in 2021 due to degrading PE-PUR soundproofing foam that could release particles and gases into the airway. Affected patients should register their devices, follow Philips safety recommendations, and consult their physician about replacement options. Patients who stopped therapy during the recall period may have experienced worsened sleep apnea, which accelerates biological aging. Dumbo Health offers biomarker-based sleep longevity testing that helps quantify how untreated or disrupted sleep therapy affects long-term health outcomes.

Key Takeaways

• Philips Respironics recalled more than 15 million CPAP, BiPAP, and ventilator devices in June 2021 due to degrading PE-PUR foam that could release toxic particles and gases into the breathing pathway
• Affected models include the DreamStation 1, SystemOne ASV4, Trilogy 200, and several BiPAP and respiratory care devices, while the DreamStation 2 was not included in the original recall
• The U.S. Food and Drug Administration classified this as a Class I recall, the most serious category, indicating a reasonable probability of serious adverse health consequences
• Patients who stopped CPAP therapy during the recall without a physician-guided alternative may have experienced worsened obstructive sleep apnea symptoms and accelerated markers of biological aging
• Dumbo Health's Core membership tests 51 sleep-longevity biomarkers twice a year for $0.99 a day, helping patients track how sleep disruption or therapy changes affect their long-term health trajectory
• ResMed, the primary alternative CPAP manufacturer, saw significant demand increases following the recall, and mandibular advancement devices offer a non-CPAP alternative for eligible patients

What Is a Philips CPAP Machine and How Does It Work

A Philips CPAP machine is a medical device manufactured by Philips Respironics that delivers continuous positive airway pressure to treat obstructive sleep apnea. The device generates a steady stream of pressurized air through a mask system to prevent the upper airway from collapsing during sleep.

Continuous positive airway pressure therapy works by splinting the airway open with a column of air delivered at a prescribed pressure setting. When a patient with obstructive sleep apnea falls asleep, the muscles in the throat relax, and in susceptible individuals, the airway narrows or closes entirely. Each closure event is called an apnea, and a partial closure is called a hypopnea. The apnea-hypopnea index, or AHI, measures the number of these events per hour during a polysomnography study or home sleep test. An AHI of 5 or higher typically indicates clinically significant sleep apnea.

Philips Respironics built its CPAP product line around several core technologies. The DreamStation platform included features such as A-Flex Pressure Relief, which reduces pressure during exhalation to improve comfort, and OptiStart Technology, which uses historical usage data to estimate the optimal starting pressure. The DreamStation line also incorporated a heated humidifier to reduce airway dryness, a cell modem for wireless data transmission to healthcare providers, and connectivity with the DreamMapper app for patient-facing sleep therapy tracking.

The company produced devices across multiple positive airway pressure therapy categories: standard CPAP for fixed-pressure delivery, auto-CPAP that adjusts pressure automatically based on detected events, and BiPAP (bilevel positive airway pressure) machines that deliver different pressures for inhalation and exhalation. BiPAP devices are typically prescribed for patients with central sleep apnea, complex sleep apnea, or certain respiratory conditions such as COPD.

DID YOU KNOW: According to the American Academy of Sleep Medicine, obstructive sleep apnea affects an estimated 30 million adults in the United States, though roughly 80 percent of moderate and severe cases remain undiagnosed.

KEY TAKEAWAY: A Philips CPAP machine treats obstructive sleep apnea by delivering continuous positive airway pressure through a mask system, using technologies such as A-Flex Pressure Relief and auto-titrating algorithms to maintain airway patency during sleep.

Understanding how these devices work is essential context for evaluating why the recall created such a significant disruption for millions of patients.

The 2021 Philips Respironics Recall: Full Timeline and Scope

Philips Respironics issued a voluntary recall of more than 15 million respiratory care devices in June 2021, making it one of the largest medical device recalls in United States history. The recall was triggered by the potential for PE-PUR sound abatement foam inside the devices to degrade, break down into particles, and release volatile organic compounds into the air pathway that patients breathe.

What Caused the Recall

The root cause was the polyester-based polyurethane (PE-PUR) foam used as soundproofing foam inside the air pathway of affected devices. This sound abatement foam was designed to reduce device noise, but Philips Respironics determined that the foam could degrade under certain conditions, particularly when exposed to heat, humidity, and certain cleaning methods such as ozone-based cleaners. When the foam degraded, black particles and chemical off-gassing could enter the airway and be inhaled or swallowed by the patient.

The U.S. Food and Drug Administration issued a safety communication in June 2021, and the agency subsequently classified the action as a Class I recall. A Class I designation is the most serious recall classification, reserved for situations where there is a reasonable probability that use of the product will cause serious adverse health consequences or death.

Affected Devices and Models

The recall covered a broad range of Philips Respironics products manufactured before April 26, 2021. Affected product lines include:

• DreamStation CPAP and Bi-level Therapy Systems (DreamStation 1 series, including the Philips DreamStation Auto CPAP Machine)
• SystemOne ASV4 (adaptive servo-ventilation for central sleep apnea and complex sleep apnea)
• Trilogy 200 ventilators (used in hospital and institutional environments and homecare settings)
• Multiple BiPAP models across the Philips Respironics portfolio
• Several respiratory care devices used for COPD, asthma, and other respiratory conditions
• Certain continuous and non-continuous ventilator models

The DreamStation 2 Advanced CPAP, which began production after the recall period, was not included in the original recall because it uses a different silicone-based foam instead of PE-PUR foam. This distinction is critical: patients and healthcare professionals should verify the exact model and serial number against the Philips Respironics recall registration portal.

Recall Remediation Plan

Philips initially committed to a recall remediation plan that involved either repairing affected devices by replacing the PE-PUR foam with silicone-based foam, or providing replacement devices. However, the remediation process experienced significant delays, leaving millions of patients without functional CPAP therapy for extended periods.

In 2024, the U.S. Food and Drug Administration and Philips agreed to a consent decree in federal district court that required Philips to take additional corrective actions, submit to FDA oversight of its manufacturing and quality processes, and fulfill specific milestones for completing device repairs and replacements. The consent decree also restricted Philips from selling or distributing certain recalled devices until the company met specific regulatory compliance requirements.

If you own a Philips CPAP or BiPAP device manufactured before April 26, 2021, register your device through the Philips Respironics recall portal and follow the safety instructions provided. Do not stop CPAP therapy without consulting your physician, because untreated obstructive sleep apnea carries its own significant health risks.

KEY TAKEAWAY: The 2021 Philips Respironics recall affected more than 15 million devices across CPAP, BiPAP, and ventilator categories due to degrading PE-PUR soundproofing foam, and a consent decree in federal district court now governs the company's corrective actions.

The health risks associated with the degraded foam became a central concern for both patients and regulatory authorities.

Health Risks From Degraded PE-PUR Foam in Philips CPAP Devices

Exposure to degraded PE-PUR foam particles and off-gassed chemicals represents a documented health risk for patients who used affected Philips CPAP machines. The severity of risk depends on the duration and extent of foam degradation, the specific device model, usage patterns, and individual patient vulnerability.

Reported Health Issues and Concerns

Philips Respironics acknowledged in medical device reports submitted to the FDA that potential health risks from inhaling or ingesting degraded foam include:

• Headache, dizziness, and irritation of the eyes, skin, nose, and respiratory tract
• Nausea, vomiting, and other gastrointestinal symptoms
• Inflammatory responses and respiratory irritation
• Toxic and potentially carcinogenic effects from chemical off-gassing
• Possible organ damage including kidney failure with prolonged exposure
• Possible increased risk of lung cancer, although long-term epidemiological data is still being evaluated

The FDA's safety communication noted that the agency had received thousands of medical device reports related to the recalled products. These reports described a range of health issues from mild respiratory irritation to more serious respiratory conditions.

The PE-PUR Foam Testing Controversy

Philips commissioned independent testing of the PE-PUR foam to assess actual patient risk. The results and their interpretation became contentious. Some testing suggested that the health risks from foam degradation were lower than initially feared under normal use conditions, while other analyses, including those reviewed by FDA scientists, raised concerns about the methodology and scope of that testing.

Healthcare professionals and the American Academy of Sleep Medicine emphasized that patients should not make unilateral decisions to stop therapy based on fear alone, because untreated obstructive sleep apnea carries well-documented risks including cardiovascular disease, stroke, hypertension, and metabolic dysfunction. The clinical priorities had to balance the known risks of untreated sleep apnea against the potential risks from foam exposure.

Thermal Issues, Overheating, and Fire Risk

Separate from the foam degradation issue, certain Philips Respironics devices also faced reports of overheating, and in rare cases fire, smoke, and burns. These thermal issues prompted additional safety communications and reinforced the FDA's classification of the recall as Class I. Patients were advised to follow safety recommendations regarding device placement, ventilation, and immediate discontinuation if they noticed visible damage, unusual smells, or black debris in the device or mask system.

DID YOU KNOW: According to FDA data, the agency received more than 100,000 medical device reports related to the Philips Respironics recall, encompassing foam degradation, off-gassing, and other device performance complaints.

KEY TAKEAWAY: Health risks from degraded PE-PUR foam in recalled Philips CPAP devices range from respiratory irritation to potential organ damage and carcinogenic exposure, but stopping CPAP therapy entirely without medical guidance also carries significant cardiovascular and metabolic health risks.

Understanding the legal landscape surrounding the recall helps patients evaluate their options and rights.

Lawsuits, Product Liability, and Regulatory Actions

Philips Respironics faces extensive legal and regulatory consequences stemming from the CPAP recall. Product liability lawsuits, class action filings, and the FDA consent decree have reshaped the company's operations and market position in the United States.

Product Liability and Negligence Claims

Thousands of patients and their families have filed lawsuits against Philips, alleging product liability, negligence, and failure to warn. The central claims in most lawsuits assert that Philips Respironics knew or should have known about the risks of PE-PUR foam degradation earlier than the 2021 recall date, that the company failed to implement adequate mitigation strategies, and that patients suffered health issues as a direct result of foam particle inhalation.

Many of these lawsuits have been consolidated into multidistrict litigation in federal district court. The legal proceedings address both personal injury claims from patients who developed respiratory conditions, lung cancer, or kidney failure, and economic loss claims from patients who paid for devices that were ultimately recalled.

The FDA Consent Decree

The consent decree agreed upon between the U.S. Food and Drug Administration and Philips in 2024 imposed binding requirements that go beyond the voluntary recall. Under the consent decree, Philips must:

• Complete the recall remediation plan under FDA supervision
• Submit to enhanced FDA inspection and oversight of manufacturing facilities
• Meet specific timelines for repairing or replacing affected devices
• Restrict sale and distribution of certain product lines until compliance milestones are met
• Maintain enhanced quality systems and regulatory compliance procedures

The consent decree represents one of the most significant FDA enforcement actions against a medical device manufacturer in recent years. It effectively limits Philips Respironics' ability to sell new respiratory care devices in the United States until the company demonstrates sustained regulatory compliance.

Impact on Customer Safety and Consumer Trust

The recall and subsequent legal actions severely damaged consumer trust in the Philips brand within the respiratory care market. Many patients who relied on Philips CPAP machines for years switched to alternative medical device manufacturers, primarily ResMed, or explored non-CPAP treatment options such as mandibular advancement devices.

For patients navigating the transition away from recalled devices, the disruption often meant extended periods without effective positive airway pressure therapy. This gap in treatment is clinically significant because untreated or undertreated obstructive sleep apnea accelerates biological aging markers. Dumbo Health's sleep longevity assessment can help patients who experienced treatment interruptions understand whether their biomarker profile shifted during the period without therapy.

KEY TAKEAWAY: Philips Respironics faces thousands of product liability and negligence lawsuits, a binding FDA consent decree governing its recall remediation, and significant erosion of consumer trust, all of which have reshaped the CPAP market in the United States.

Patients affected by the recall need a clear framework for evaluating their current CPAP options.

Philips CPAP Models: DreamStation 1 vs DreamStation 2 and Beyond

The distinction between recalled and non-recalled Philips models is one of the most critical decisions for current and prospective CPAP users. Not all Philips CPAP machines carry the same risk profile.

DreamStation 1 (Recalled)

The original DreamStation platform, often referred to as DreamStation 1, is included in the recall. This line encompassed CPAP, auto-CPAP, and BiPAP configurations. Key features of the DreamStation 1 included:

• A-Flex Pressure Relief for exhalation comfort
• OptiStart Technology for automatic pressure optimization
• Heated humidifier integration
• Cell modem for wireless compliance data reporting
• DreamMapper connectivity for patient-facing therapy tracking
• Compact design with a color display

DreamStation 1 devices manufactured before April 26, 2021, used PE-PUR soundproofing foam in the air pathway, which is the component subject to the recall. Patients using any DreamStation 1 device should confirm their registration status through Philips Respironics and follow all safety instructions for continued use or repair and replacement.

DreamStation 2 (Not Recalled)

The DreamStation 2 Advanced CPAP was designed with a different construction that uses silicone-based foam instead of PE-PUR foam. This change directly addressed the degradation issue that triggered the recall. The DreamStation 2 entered production after the recall and was specifically engineered to avoid the material that caused the safety concern.

However, the DreamStation 2's availability in the United States market has been affected by the consent decree. Under the decree, Philips paused sales of new sleep therapy devices in the United States until it meets the FDA's requirements, so most patients cannot get a new DreamStation 2 today. Existing devices continue to be serviced.

Other Affected Philips Respironics Devices

Beyond the DreamStation line, the recall includes:

• SystemOne ASV4 adaptive servo-ventilation devices used for central sleep apnea
• Trilogy 200 ventilators used in both homecare and hospital and institutional environments
• Various legacy CPAP and BiPAP models under the Philips Respironics brand
• Certain respirator machines and respiratory care devices

Comparison: DreamStation 1 vs DreamStation 2

Foam Material

• DreamStation 1: PE-PUR soundproofing foam (recalled)
• DreamStation 2: Silicone-based foam (not recalled)

Recall Status

• DreamStation 1: Included in 2021 Class I recall
• DreamStation 2: Not included in the recall

Key Technologies

• DreamStation 1: A-Flex, OptiStart, Heated Humidifier, Cell Modem, DreamMapper
• DreamStation 2: Updated pressure relief algorithms, Bluetooth connectivity, redesigned humidifier

Availability

• DreamStation 1: No longer sold; recalled units eligible for repair or replacement
• DreamStation 2: New US sales paused under the consent decree; confirm current status with your provider

Best For

• DreamStation 1: Not recommended for continued use without completing recall remediation
• DreamStation 2: Patients who prefer staying within the Philips ecosystem and can confirm availability through their provider

For patients considering a complete brand switch, ResMed's AirSense line has become the primary alternative in the CPAP market. The choice between Philips and ResMed now involves evaluating not just device features but also regulatory history, supply reliability, and long-term brand trust.

KEY TAKEAWAY: The DreamStation 2 uses silicone-based foam instead of PE-PUR foam and was not part of the 2021 recall, but its availability has been constrained by the consent decree governing Philips Respironics' operations.

Choosing the right device is only part of the equation for patients whose therapy was disrupted.

The Hidden Cost of CPAP Disruption: How Treatment Gaps Accelerate Biological Aging

Treatment interruptions from the Philips recall did not just disrupt sleep therapy; they may have accelerated biological aging in affected patients. This connection between therapy gaps and measurable health decline is one of the most underreported consequences of the recall.

Obstructive sleep apnea, when left untreated, triggers a cascade of physiological stress responses. Each apnea event causes oxygen desaturation, sympathetic nervous system activation, and cortisol surges. Over weeks and months, these repeated micro-stressors drive chronic inflammation, insulin resistance, and endothelial dysfunction. According to the National Heart, Lung, and Blood Institute, untreated sleep apnea is associated with increased risk of hypertension, heart failure, stroke, type 2 diabetes, and cognitive decline.

What makes this relevant to Philips recall patients specifically is the duration of the disruption. Many patients went months or even years with delayed remediation. During that period, the biological damage from untreated sleep apnea did not pause. Blood biomarkers such as HbA1c (a marker of glucose regulation), hs-CRP (a marker of systemic inflammation), and ApoB (a marker of cardiovascular risk) may have shifted unfavorably.

The emerging field of sleep longevity science now allows patients to measure this impact directly. Dumbo Health's SleepLongevityAge metric combines 51 or more blood biomarkers with optional wearable data from devices such as Oura, Whoop, and Garmin to calculate how sleep is accelerating or slowing biological aging. For patients who experienced therapy gaps during the recall, this type of assessment provides a concrete starting point for recovery rather than guessing whether the disruption caused lasting harm.

The Core membership at Dumbo Health tests 51 sleep-longevity biomarkers twice a year through the Quest Diagnostics network, with more than 2,000 locations across the United States. Blood draws are available near you at a Quest location, and roughly 9 in 10 people live within 20 minutes of a draw site. The cost is $0.99 a day for early members, billed annually at $365 a year, with no insurance required, no prior authorizations, and HSA and FSA eligibility.

TIP: If your CPAP therapy was interrupted for more than 30 days during the Philips recall, consider getting a baseline biomarker panel to assess whether inflammation, metabolic, or cardiovascular markers shifted during the gap.

KEY TAKEAWAY: Extended CPAP therapy interruptions caused by the Philips recall may have accelerated biological aging markers in affected patients, and biomarker testing through a program like Dumbo Health can quantify that impact and guide a recovery plan.

Knowing the damage is step one. Understanding what to do next requires a clear action plan.

What to Do If You Own a Recalled Philips CPAP Machine

Patients who own a recalled Philips CPAP or BiPAP device should take specific, sequential steps to protect their health and maintain effective sleep apnea treatment. Doing nothing is the highest-risk option, both from a foam exposure standpoint and from the consequences of untreated sleep apnea.

Step-by-Step Action Plan for Affected Patients

1. Identify your device model and serial number by checking the label on the back or bottom of the unit, then verify whether your specific model appears on the Philips Respironics recall list.
2. Register your device through the Philips Respironics recall portal using your device serial number, contact email, and shipping information to track your remediation status.
3. Contact your prescribing physician or sleep specialist to discuss whether to continue using the device, switch to an alternative device, or explore a non-CPAP treatment pathway such as mandibular advancement devices.
4. Follow all Philips safety instructions, including avoiding the use of ozone-based cleaning products, inspecting the device for visible foam degradation or black particles, and discontinuing use immediately if you notice smoke, unusual odors, or visible debris.
5. Request a replacement or repaired device through the Philips remediation program if your device is confirmed as recalled and eligible for repair or replacement.
6. If transitioning to a new CPAP or BiPAP device from another manufacturer such as ResMed, work with your healthcare provider to confirm your current pressure prescription and mask compatibility (the DreamWear Mask System and similar Philips masks may need to be replaced with compatible alternatives from other brands).
7. Take the free quiz at Dumbo Health to see which path fits you, and consider establishing a new biomarker baseline to check whether your therapy disruption has affected your sleep-related biomarkers.

After completing these steps, you will have a clear record of your recall status, a physician-guided therapy plan, and a baseline understanding of your current health trajectory.

Checklist Before Resuming or Replacing CPAP Therapy

• Confirm your device model is either cleared for continued use, repaired with silicone-based foam, or replaced
• Verify your CPAP prescription is current (some insurers and Medicare may ask for updated sleep study or visit documentation)
• Inspect all mask components, cushions, tubing, and humidifier chambers for wear or contamination
• Update your DreamMapper or replacement sleep tracking app with your new device information
• Confirm your insurance, Medicare, or self-pay coverage for the replacement device and supplies
• Request updated compliance data if you use a cell modem or Bluetooth-connected device for provider reporting
• Schedule a follow-up polysomnography or home sleep apnea test if your AHI was not recently measured
• Book a biomarker blood draw through Dumbo Health's Quest Diagnostics network to establish a post-disruption health baseline

KEY TAKEAWAY: Patients with recalled Philips CPAP devices should register their device, consult their physician, follow safety instructions, and establish a new baseline through both a sleep study and biomarker testing to ensure their therapy transition does not leave health gaps unaddressed.

Beyond the immediate recall response, many patients are now reevaluating how they approach sleep apnea treatment more broadly.

CPAP Alternatives and the Broader Sleep Apnea Treatment Landscape

CPAP therapy remains the gold standard for moderate to severe obstructive sleep apnea, but the Philips recall prompted many patients to explore alternative treatment pathways. Understanding the full range of options helps patients make informed decisions rather than reactive ones.

ResMed as the Primary CPAP Alternative

Following the Philips recall and subsequent market withdrawal of certain product lines, ResMed became the dominant CPAP manufacturer in the United States. ResMed's AirSense product line, including the AirSense 10 and AirSense 11, does not use PE-PUR foam and was not subject to the recall. ResMed experienced significant demand increases during and after the recall period, and the brand now holds the majority of new CPAP prescriptions filled through homecare providers and durable medical equipment suppliers in the United States.

Healthcare professionals, including those affiliated with the American Academy of Sleep Medicine, generally regard both Philips (post-remediation DreamStation 2) and ResMed devices as clinically effective when properly prescribed and titrated. The choice between them now involves weighing device features, availability, provider relationships, and patient comfort preferences.

Mandibular Advancement Devices

For patients with mild to moderate obstructive sleep apnea who cannot tolerate positive airway pressure therapy, mandibular advancement devices (MADs) offer a non-CPAP alternative. These custom-fitted oral appliances reposition the lower jaw forward during sleep to prevent airway collapse. The American Academy of Dental Sleep Medicine supports the use of MADs for appropriately selected patients, though efficacy varies based on the severity of sleep apnea and individual anatomy.

MADs do not address central sleep apnea and are generally less effective than CPAP for severe obstructive sleep apnea (AHI above 30). Patients considering MADs should undergo a thorough evaluation, ideally including a polysomnography or home sleep apnea test, to confirm candidacy.

At-Home Sleep Apnea Testing

Regardless of which treatment pathway a patient chooses, accurate diagnosis is the foundation. Dumbo Health offers an FDA-cleared at-home sleep apnea test for $149 in Florida, Texas, Virginia and Maryland, with physician diagnosis typically within 48 hours. This option removes common barriers such as long wait times for in-lab polysomnography and insurance pre-authorization delays. For patients who lost track of their sleep apnea severity during the recall disruption, re-testing provides the data needed to optimize their next treatment decision.

Sleep Apnea Care as Part of a Longevity Strategy

The most forward-looking approach treats sleep apnea diagnosis and CPAP therapy not as isolated clinical events but as components of a broader longevity strategy. At Dumbo Health, sleep apnea testing and CPAP care are separate from the sleep longevity membership, but they work well together: patients who start with a sleep apnea test can add ongoing biomarker tracking and SleepLongevityAge monitoring to understand the systemic effects of sleep disruption rather than just the mechanical airway problem.

KEY TAKEAWAY: ResMed is the primary CPAP alternative following the Philips recall, mandibular advancement devices serve eligible patients with mild to moderate apnea, and combining any treatment choice with ongoing biomarker monitoring creates a more complete approach to managing sleep apnea's long-term health impact.

Cost and coverage are often the deciding factor in how patients navigate the post-recall landscape.

Cost, Insurance, and Medicare Considerations for CPAP Replacement

Replacing a recalled Philips CPAP machine involves financial decisions that vary based on insurance status, Medicare eligibility, and the specific replacement pathway chosen. Transparency around cost is essential for patients who may already feel burned by the recall experience.

Insurance and Medicare Coverage

Most private insurance plans and Medicare cover CPAP and BiPAP devices when medically necessary, meaning the patient has a qualifying sleep study (polysomnography or approved home sleep test) demonstrating an AHI of 5 or higher with symptoms, or an AHI of 15 or higher regardless of symptoms. The Centers for Medicare and Medicaid Services requires specific compliance documentation, typically showing at least 4 hours of CPAP use per night for at least 70 percent of nights during an initial evaluation period, before authorizing ongoing coverage of supplies.

Patients whose Philips devices were recalled may need updated sleep study data to qualify for replacement device coverage, particularly if their most recent study is more than 2 years old. Some homecare providers, including Lincare and other large durable medical equipment suppliers, have dedicated recall support teams to help patients navigate the replacement process.

Self-Pay and Cash-Pay Options

For patients without insurance, with high-deductible plans, or who prefer to avoid authorization delays, a cash-pay CPAP plan is an option. Dumbo Health CPAP plans start at $59 a month and include the machine, a mask fitted to your face, resupply and a care team. Dumbo Health CPAP care is available in Florida, Texas, Virginia and Maryland.

Masks, cushions, heated humidifier chambers, tubing, and filters represent ongoing supply costs. Most mask systems need replacement components every 1 to 6 months depending on the component.

Where Dumbo Health Fits in the Cost Equation

Dumbo Health's approach addresses a gap that neither insurance nor traditional CPAP suppliers cover: the ongoing biological cost of sleep disruption. While insurance covers the device and supplies, nobody typically measures whether the therapy is actually reversing the systemic damage that untreated sleep apnea causes. The Core plan at $0.99 a day tracks 51 sleep-longevity biomarkers twice a year, giving patients objective data on whether their treatment is moving the needle on inflammation, metabolic health, and cardiovascular risk markers. All plans are HSA and FSA eligible, cash-pay, and require no insurance, no prior authorizations, and no surprise bills.

For patients who want the most comprehensive approach, the Concierge plan at $300 a month for early members includes 103 biomarkers tested twice a year, a dedicated sleep physician with 24/7 access, a personal sleep coach, and all add-on specialty packs. Early-member pricing locks for life for the first 500 members.

KEY TAKEAWAY: CPAP replacement costs vary widely based on insurance status and device choice, but the often-overlooked cost is the biological damage from untreated or disrupted therapy, which biomarker testing through Dumbo Health can quantify and track at a predictable, cash-pay price.

Not every patient situation is straightforward, and some face limitations that standard guidance does not address.

Limitations and Risks: When Standard Recall Guidance May Not Be Enough

Standard recall guidance from Philips Respironics and the FDA covers device registration, repair, and replacement, but it does not address every patient's clinical reality. Certain situations require more nuanced decision-making.

Limitation 1: Delayed Remediation Timelines

Despite the consent decree and FDA oversight, some patients report waiting 12 months or longer for repair or replacement of their recalled device. During this period, patients face a difficult choice: continue using a device with potentially degraded foam, stop therapy and risk the cardiovascular and metabolic consequences of untreated sleep apnea, or start on a new device through a prescribing provider. There is no universally correct answer, and the right decision depends on the individual's AHI severity, comorbidities, and financial situation. Physicians should evaluate each case individually and document the clinical rationale.

Limitation 2: Limited Availability of DreamStation 2

The consent decree restricts Philips Respironics' manufacturing and distribution, which means the DreamStation 2 may not be readily available in your area. Patients who specifically prefer Philips devices may need to consider ResMed or other manufacturers as an interim or permanent alternative. Healthcare professionals should verify current availability through their homecare provider network before committing patients to a specific brand.

Limitation 3: Biomarker Damage Assessment Is Not Standard of Care

While Dumbo Health and the broader longevity medicine community advocate for biomarker testing to assess the impact of therapy disruption, this approach is not yet part of standard sleep medicine practice. Most sleep physicians focus on device compliance data and AHI scores rather than systemic biomarkers. Patients interested in a biomarker-based assessment may need to seek it out independently. Dumbo Health helps bridge this gap with its physician-reviewed biomarker panel and longevity offerings, but patients should understand that this is an emerging approach rather than a universally established clinical standard.

Limitation 4: Foam Exposure Risk Quantification Is Uncertain

The long-term health effects of PE-PUR foam exposure remain uncertain. While some studies suggest the risk under normal use conditions may be lower than initially feared, the FDA has not issued a definitive clearance of the recalled devices. Patients who experienced visible foam degradation, black particles, or unusual symptoms should report these to their physician and to the FDA's MedWatch system. Long-term epidemiological data on outcomes such as lung cancer and kidney failure in exposed patients is still being collected.

Limitation 5: State-Specific Telehealth and Testing Availability

For patients seeking sleep apnea diagnosis or follow-up care through telehealth platforms, availability varies by state. Dumbo Health's at-home sleep apnea test and CPAP care are currently available in Florida, Texas, Virginia and Maryland. Patients in other states should work with a local sleep specialist. Dumbo Health's biomarker testing is available in 49 states and Washington DC but is not currently available in Rhode Island.

KEY TAKEAWAY: Standard recall guidance does not account for prolonged remediation delays, limited device availability, uncertain long-term exposure risks, or the systemic biological impact of therapy gaps, all of which require individualized physician-guided decision-making.

Real-world scenarios illustrate how these limitations play out for actual patients.

Real-World Scenarios: How Patients Navigate the Post-Recall Landscape

Patient experiences with the Philips CPAP recall vary widely based on their clinical severity, insurance status, geographic location, and willingness to explore alternative approaches. These scenarios represent common patterns observed across the recall population.

Scenario 1: The Long-Term DreamStation User With No Symptoms

A 58-year-old man has used a Philips DreamStation 1 Auto CPAP for 6 years. His AHI was well-controlled at 3 events per hour with therapy. When the recall was announced, he inspected his device, found no visible foam degradation, and registered for remediation. After 14 months without receiving a replacement, he switched to a ResMed AirSense 11 through his provider. He continued therapy without significant interruption but never had any biomarker testing to assess whether 6 years of potential low-level foam exposure had any measurable effect. A patient in this situation could benefit from Dumbo Health's Core membership to establish a biomarker baseline, particularly for inflammatory markers like hs-CRP and metabolic markers like HbA1c, for $0.99 a day.

Scenario 2: The Medicare Patient Who Stopped Therapy

A 67-year-old woman on Medicare stopped using her recalled Philips BiPAP device immediately after the recall announcement because she was concerned about the health risks. She did not have a backup device and waited for Philips to provide a replacement. During the 10-month gap, her daytime sleepiness returned, her blood pressure increased, and her primary care physician noted worsening glucose control. When she finally received a replacement device, she also needed updated documentation from her physician before Medicare would cover the new device. Her experience illustrates why the American Academy of Sleep Medicine cautioned against abruptly stopping therapy without physician guidance. Patients in similar situations who want to assess the biological impact of their therapy gap can start with Dumbo Health's free quiz.

Scenario 3: The Health-Optimized Professional Who Uses the Recall as a Reset

A 45-year-old executive was diagnosed with mild obstructive sleep apnea (AHI of 12) three years before the recall and used a DreamStation 1 CPAP with moderate adherence. The recall prompted her to reassess her entire approach to sleep health. She switched to a ResMed device, added an Oura ring for nightly sleep tracking, and enrolled in Dumbo Health's Concierge plan to get 103 biomarkers tested twice a year with a dedicated sleep physician and personal sleep coach. Her SleepLongevityAge assessment showed that her biological age was tracking 4 years above her chronological age, largely driven by elevated cortisol and suboptimal deep sleep. By combining optimized CPAP therapy with the Circadian and Stress add-on pack ($269) and ongoing physician support, she developed a targeted plan to close the gap between her biological and chronological age.

KEY TAKEAWAY: The post-recall experience varies dramatically based on patient circumstances, but in every scenario, the combination of appropriate device replacement, ongoing sleep monitoring, and biomarker-based health assessment produces better long-term outcomes than device replacement alone.

With real scenarios in context, addressing common misconceptions helps patients separate fact from fear.

Common Myths About the Philips CPAP Recall and Sleep Apnea Treatment Debunked

MYTH: All Philips CPAP machines are dangerous and should be thrown away immediately.

FACT: The recall specifically affects devices containing PE-PUR soundproofing foam, primarily those manufactured before April 26, 2021. The DreamStation 2, which uses silicone-based foam, was not included in the recall. The U.S. Food and Drug Administration recommends registering affected devices and following the recall remediation plan rather than disposing of them, because abruptly stopping CPAP therapy without a replacement creates its own serious health risks.

MYTH: If I did not see black particles in my CPAP, the foam did not degrade.

FACT: Foam degradation can produce both visible particles and invisible chemical off-gassing. The absence of visible black debris does not confirm that the foam remained intact throughout the device's lifespan. The FDA's safety communication noted that chemical off-gassing can occur without visible physical breakdown. Patients should not rely on visual inspection alone to assess exposure risk.

MYTH: CPAP therapy only matters for snoring and daytime sleepiness.

FACT: Obstructive sleep apnea drives systemic health consequences that extend far beyond snoring. According to the National Heart, Lung, and Blood Institute, untreated sleep apnea is associated with hypertension, heart failure, stroke, type 2 diabetes, and cognitive decline. Research increasingly shows that untreated sleep apnea accelerates biological aging by driving chronic inflammation, oxidative stress, and metabolic dysfunction, which is why measuring sleep-related biomarkers provides a more complete picture than AHI scores alone.

MYTH: The recall was overblown and Philips devices are safe to keep using without any action.

FACT: The FDA classified this as a Class I recall, the most serious category, and entered a consent decree in federal district court requiring Philips to take specific corrective actions under government oversight. Regardless of individual risk assessment, the regulatory and legal framework confirms that the safety concern was substantive enough to warrant the highest level of enforcement.

MYTH: Once I replace my CPAP, my health will return to normal automatically.

FACT: Resuming effective CPAP therapy addresses ongoing apnea events, but it does not automatically reverse biological damage accumulated during a therapy gap. Biomarkers related to inflammation, cardiovascular risk, and metabolic health may remain elevated even after therapy resumes. Tracking these markers over time, such as through Dumbo Health's biomarker testing program, provides objective evidence of whether recovery is on track.

KEY TAKEAWAY: The most dangerous myths about the Philips CPAP recall lead patients to either overreact by stopping therapy entirely or underreact by assuming no action is needed, when the evidence-based path requires device remediation, continued therapy, and proactive health monitoring.

Conclusion

The Philips CPAP machine recall reshaped how millions of sleep apnea patients think about their devices, their treatment continuity, and their long-term health. Whether you are navigating a device replacement, considering a switch to ResMed, or simply trying to understand what the recall means for your health going forward, the most important step is to keep treating your sleep apnea while monitoring the broader biological impact.

Replacing a recalled device addresses the immediate safety concern. Measuring what happened to your body during the disruption addresses the longer-term question that most patients never think to ask. Dumbo Health's sleep longevity membership starts at $0.99 a day for 51 biomarkers tested twice a year, requires no insurance, and is HSA and FSA eligible, giving you a clear, affordable way to track whether your sleep health recovery is actually working.

Frequently Asked Questions About Philips CPAP Machines

What is a CPAP machine and how does it work?

A CPAP machine, short for continuous positive airway pressure device, is a medical device that treats obstructive sleep apnea by delivering a steady stream of pressurized air through a mask to keep the upper airway open during sleep. When a person with sleep apnea falls asleep, the muscles in the throat relax and partially or fully block the airway, causing breathing interruptions. The continuous airflow from a CPAP machine acts as a pneumatic splint, preventing those collapses. The American Academy of Sleep Medicine recognizes CPAP therapy as the standard first-line treatment for moderate to severe obstructive sleep apnea.

Do I need a CPAP machine?

Whether you need a CPAP machine depends on a clinical evaluation, not self-assessment. A healthcare professional can determine whether CPAP therapy is appropriate based on your symptoms, a home sleep apnea test, or an in-lab sleep study such as polysomnography, along with your apnea-hypopnea index score. Common indicators that a clinician might consider include loud snoring, witnessed breathing pauses, excessive daytime sleepiness, or confirmed obstructive sleep apnea. If you are experiencing these symptoms, speak with a qualified healthcare professional before purchasing any sleep therapy device.

What is the Philips Respironics CPAP recall and what devices are affected?

In June 2021, Philips Respironics issued a voluntary recall affecting certain CPAP, BiPAP, and mechanical ventilator devices due to concerns about the polyester-based polyurethane foam, known as PE-PUR foam, used for sound abatement inside the devices. The U.S. Food and Drug Administration classified this as a Class I recall, the most serious category, indicating that the recalled products could cause serious injury or death. Affected devices included the DreamStation 1 series, DreamStation CPAP and Bi-level Therapy Systems, SystemOne ASV4, Trilogy 200, and several other respiratory care devices. The DreamStation 2 was not part of the original recall scope. Patients with affected devices were advised to consult their healthcare professionals before stopping therapy.

What health risks are associated with the Philips CPAP PE-PUR foam?

The PE-PUR sound abatement foam used in recalled Philips Respironics devices was found to potentially degrade and release particles or gases that users could inhale or ingest. According to the FDA's safety communication, potential health risks included irritation to the airway, headaches, coughing, chest pressure, and in more serious assessments, possible carcinogenic or toxic effects from certain off-gassed chemicals. Concerns raised in medical device reports and testing included possible links to respiratory conditions, kidney failure, and lung cancer, though individual risk varies depending on device model, usage duration, environmental conditions such as heat and humidity, and whether unauthorized cleaning methods such as ozone were used. A healthcare professional can help assess your individual situation.

What should I do if I have a recalled Philips CPAP machine?

If you have a recalled Philips Respironics device, the most important first step is to consult your healthcare professional before stopping or changing your sleep apnea therapy. The FDA advised that the health risks of untreated obstructive sleep apnea may outweigh the risks of continued device use in certain patients, particularly those with severe sleep apnea. Patients were encouraged to register their device on the Philips recall remediation portal and follow official safety recommendations. Do not use ozone or UV cleaning methods, which can accelerate foam degradation. Check the FDA recall page for current guidance and consult your clinician for personalised safety instructions.

What is the difference between the Philips DreamStation 1 and DreamStation 2?

The Philips DreamStation 1 was part of the 2021 Philips Respironics recall due to concerns about PE-PUR foam degradation. The DreamStation 2 is a newer platform that Philips developed with a different sound abatement design and was not included in the original recall. The DreamStation 2 features include updated OptiStart Technology, A-Flex Pressure Relief for patient comfort, a heated humidifier option, and compatibility with DreamMapper for remote monitoring. However, regulatory compliance and current device availability should be confirmed directly with a healthcare provider or qualified supplier, as production, sale, and support status may have changed following the consent decree entered into between Philips and the federal district court.

How long will I need to use a CPAP machine?

For most people with obstructive sleep apnea, CPAP therapy is an ongoing, long-term treatment rather than a short-term intervention. Sleep apnea is a chronic condition, and continuous positive airway pressure therapy works only while it is being used. Stopping treatment typically means symptoms return. Some patients may explore alternative treatments such as mandibular advancement devices, positional therapy, or surgical options, but these decisions should be made with a qualified sleep physician based on individual health factors, severity of sleep apnea as measured by the apnea-hypopnea index, and clinical response to therapy. A healthcare professional can advise on the most appropriate long-term treatment plan for your situation.

How long does it take for CPAP therapy to work?

Many people begin to notice improvements in daytime sleepiness and energy levels within the first one to two weeks of consistent CPAP use, though individual results vary. Full benefits, including improvements in blood pressure, cognitive function, and cardiovascular health markers, may take several weeks to months of regular use. The key factor is adherence. Medicare and most clinical guidelines define adequate CPAP adherence as using the device for at least four hours per night on 70 percent of nights over a consecutive 30-day period. If you are not noticing improvement after several weeks, a sleep physician can review your therapy data and make adjustments to pressure settings, mask fit, or humidifier settings.

How do I know if CPAP therapy is working for me?

CPAP therapy is generally considered effective when your apnea-hypopnea index readings from the device fall below five events per hour, you are sleeping through the night with fewer interruptions, daytime sleepiness improves, and your mask fit is comfortable and leak-free. Most modern CPAP machines, including Philips DreamStation models and ResMed devices, record nightly therapy data that a clinician can review remotely or in person. If you are unsure whether your therapy is working, your sleep physician can assess your device data, mask seal, and symptom progression. Do not adjust pressure settings on your own without clinician guidance.

What is the difference between CPAP and BiPAP therapy?

CPAP, or continuous positive airway pressure, delivers a single fixed pressure throughout both inhalation and exhalation. BiPAP, or bilevel positive airway pressure, delivers two distinct pressure levels: a higher pressure during inhalation and a lower pressure during exhalation, which some patients find more comfortable. BiPAP is often prescribed for patients with COPD, central sleep apnea, respiratory conditions requiring greater ventilatory support, or those who cannot tolerate the continuous pressure of standard CPAP. Both types of devices were included in the 2021 Philips Respironics recall. A sleep physician determines which therapy type is appropriate based on clinical findings, polysomnography results, and individual respiratory needs.

What is a mandibular advancement device and how does it compare to CPAP?

A mandibular advancement device, or MAD, is an oral appliance fitted by a dentist, often trained through the American Academy of Dental Sleep Medicine, that repositions the lower jaw slightly forward during sleep to help keep the upper airway open. MADs are typically recommended for patients with mild to moderate obstructive sleep apnea or for those who cannot tolerate CPAP therapy. CPAP remains the more effective treatment for moderate to severe sleep apnea as measured by the apnea-hypopnea index, but MADs offer a non-machine alternative that some patients find easier to use consistently. A sleep physician or qualified dentist can advise on which option suits your severity and lifestyle.

What product liability claims have been filed against Philips related to the CPAP recall?

Following the 2021 Philips Respironics recall, thousands of product liability lawsuits were filed in the United States by patients who alleged they suffered health complications, including respiratory conditions, lung cancer, kidney failure, and other injuries, after using recalled CPAP and BiPAP devices. These lawsuits claimed that Philips and its subsidiaries were negligent in their design, manufacturing, and disclosure of health risks related to PE-PUR foam degradation. Many cases were consolidated into multidistrict litigation in federal district court. If you believe you or a loved one suffered medical complications from a recalled Philips Respironics device, consulting a qualified attorney who handles medical device product liability cases is the appropriate first step. Dumbo Health does not provide legal advice.

What type of compensation can be sought in a Philips CPAP product liability claim?

In product liability claims related to recalled Philips CPAP and BiPAP devices, plaintiffs have generally sought compensation for medical expenses, ongoing healthcare costs related to alleged injuries, lost income, pain and suffering, and in wrongful death cases, damages on behalf of surviving family members. The specific compensation available depends on the individual case, jurisdiction, documented injuries, and evidence linking device use to health harm. These are legal determinations made through the courts, not medical determinations. Anyone considering a claim should consult a licensed attorney with experience in medical device product liability, as eligibility criteria, timelines, and legal standards vary. Dumbo Health does not provide legal advice or representation.

When should I consider filing a Philips CPAP recall claim?

If you used a recalled Philips Respironics CPAP or BiPAP device and subsequently experienced health complications such as respiratory illness, airway irritation, or a more serious condition, you may want to speak with a product liability attorney to understand whether you have a viable claim. Legal claims related to medical device harm are typically subject to statutes of limitations that vary by state, which means waiting too long may affect your ability to file. Documenting your device model, serial number, usage history, and any medical treatment you received is an important first step. This is a legal matter, not a medical one, and Dumbo Health does not provide legal guidance. Seek qualified legal counsel to evaluate your situation.

Is there an at-home sleep apnea test available if I need a new sleep apnea diagnosis or want to switch devices?

Yes. If your recalled Philips device is no longer in use and you need a current sleep apnea evaluation, an at-home home sleep apnea test (HSAT) is a convenient, clinically validated option for most patients with suspected obstructive sleep apnea. The American Academy of Sleep Medicine supports the use of home sleep apnea testing for appropriate candidates. In Florida, Texas, Virginia and Maryland, Dumbo Health offers a $149 at-home sleep apnea test with physician diagnosis typically within 48 hours, transparent cash-pay pricing, and no insurance required. This can be a practical next step if you need updated documentation, a new prescription, or want to explore CPAP therapy options with physician support. You can get an at-home sleep apnea test directly through Dumbo Health.

Does Medicare cover Philips CPAP machines or replacement devices after the recall?

Medicare may cover CPAP equipment, including replacement devices, when a beneficiary has a documented diagnosis of obstructive sleep apnea and meets adherence requirements set by the Centers for Medicare and Medicaid Services. Coverage typically requires a qualifying sleep study, a physician prescription, and demonstrated compliance with therapy over a monitored period. Following the Philips recall, many patients needed replacement devices, and Medicare coverage eligibility for replacements depended on individual circumstances, supplier contracts, and regulatory compliance of the new device. Contact your Medicare supplier or healthcare provider directly to clarify your current coverage status, as rules and device availability may have changed following the recall and the Philips consent decree.

Can a home sleep apnea test replace a full in-lab polysomnography study?

A home sleep apnea test can be an appropriate diagnostic tool for many adults with a high likelihood of moderate to severe obstructive sleep apnea, but it has limitations compared to a full in-lab polysomnography study. Home sleep tests measure airflow, breathing effort, oxygen saturation, and heart rate, but they do not capture full sleep staging, brain wave activity, or leg movements. They may underestimate the severity of sleep apnea and are generally not recommended for patients with suspected central sleep apnea, COPD, significant cardiac conditions, or other complex respiratory conditions. A sleep physician can advise whether a home sleep apnea test is appropriate for your situation or whether an in-lab study is clinically necessary.

How does ResMed compare to Philips Respironics for CPAP therapy?

ResMed is the other major global manufacturer of CPAP and BiPAP devices and was not involved in the 2021 Philips Respironics recall. ResMed devices, including the AirSense series, use different sound abatement materials and were not subject to the same PE-PUR foam safety concerns. Many patients who discontinued use of recalled Philips devices transitioned to ResMed equipment during and after the recall. Both brands offer auto-titrating CPAP devices, heated humidifiers, remote data monitoring, and a range of masks and cushions. The right device for any individual patient depends on clinical prescription, comfort, mask fit, and a prescribing physician's recommendation, not brand preference alone.

What should commercial drivers know about sleep apnea and CPAP compliance?

Commercial drivers with a CDL are subject to FMCSA health standards, and sleep apnea is a recognized factor that certified medical examiners may consider during a DOT physical. According to the FMCSA, drivers with untreated obstructive sleep apnea may not meet the medical standards required for a commercial driver's license. If a driver is prescribed CPAP therapy, adherence data is often reviewed by a certified medical examiner at renewal. A certified medical examiner makes all DOT certification decisions; Dumbo Health supports testing and care documentation but does not guarantee DOT certification or medical clearance. Commercial drivers seeking a home sleep apnea test can find relevant guidance on sleep apnea testing for CDL drivers.

What is the consent decree between Philips and the federal district court?

In 2024, Philips Respironics entered into a consent decree with the U.S. Department of Justice and the FDA, filed in federal district court, requiring Philips to meet specific corrective action and regulatory compliance obligations related to its recalled respiratory care devices. The consent decree imposed restrictions on the production and sale of certain devices in the United States until Philips demonstrated compliance with FDA quality system requirements. This affected device availability, recall remediation timelines, and Philips's ability to manufacture and sell new CPAP and respiratory care devices under US standards. Patients seeking current information on device availability and regulatory status should consult the FDA's official communications or their healthcare provider.

How can biomarker testing support my sleep health beyond CPAP therapy?

CPAP therapy addresses airway obstruction during sleep, but it does not directly measure or address the broader biological effects of chronic poor sleep on metabolic health, inflammation, cardiovascular risk, and biological aging. Biomarker testing can provide a more complete picture of how sleep quality may be affecting your body over time. Dumbo Health's sleep longevity biomarker panel measures up to 103 markers covering metabolic, hormonal, inflammatory, and cardiovascular health, and generates a SleepLongevityAge score that tracks how sleep may be accelerating or slowing biological aging. A physician reviews your results and can help interpret what abnormal findings may mean for your individual health. Biomarker testing is a wellness and screening tool, not a diagnostic replacement for clinical care.

How do I find blood draw or sleep testing locations near me?

If you need a blood draw for biomarker testing or want to find sleep apnea testing support in your area, Dumbo Health works with a network of lab locations to make at-home and nearby testing accessible. You can find a testing location near you through the Dumbo Health platform. For at-home sleep apnea testing, the device is mailed directly to you and returned after use, so no in-person lab visit is required for the sleep test itself. Dumbo Health's sleep apnea test and CPAP care are currently available in Florida, Texas, Virginia and Maryland.

Is CPAP equipment and care available through Dumbo Health?

Yes, in Florida, Texas, Virginia and Maryland. The at-home sleep apnea test is $149 as a one-time purchase, and includes one night of FDA-cleared home testing with physician diagnosis typically within 48 hours. If CPAP is prescribed, CPAP therapy is a separate cash-pay CPAP plan from $59 a month: the machine, a mask fitted to your face, resupply reminders triggered by your device data, and a care team, and you can cancel anytime. The sleep longevity membership does not include CPAP equipment or resupply. No insurance is required, with no prior authorizations and no surprise bills. You can explore sleep apnea care by taking the free quiz to see which path fits your situation.